Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 476.93M P/E - EPS this Y - Ern Qtrly Grth -
Income -57.11M Forward P/E -7.40 EPS next Y - 50D Avg Chg 3.00%
Sales 2.1M PEG - EPS past 5Y - 200D Avg Chg -38.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -89.00%
Recommedations 2.00 Quick Ratio 2.08 Shares Outstanding 109.97M 52W Low Chg 44.00%
Insider Own 47.45% ROA -62.74% Shares Float 57.69M Beta 1.16
Inst Own 1.34% ROE -149.31% Shares Shorted/Prior 523.24K/2.79M Price 5.33
Gross Margin 100.00% Profit Margin - Avg. Volume 91,312 Target Price 2.00
Oper. Margin -1,431.62% Earnings Date - Volume 12,368 Change 1.52%
About Apollomics Inc.

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Apollomics Inc. News
11/21/24 Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
09/16/24 Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
09/04/24 Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/14/24 Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
08/13/24 Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
08/08/24 Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
07/16/24 Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
07:00 AM Apollomics Announces Updated Strategic Focus and Leadership Team Changes
06/04/24 Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
05/29/24 Apollomics Announces Presentation at the 2024 BIO International Convention
05/08/24 Apollomics Announces Private Placement Financing and Addition to Board of Directors
04/25/24 Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
04/10/24 Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
04/02/24 Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
03/28/24 Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
03/26/24 Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
03/04/24 Apollomics Names Matthew Plunkett as Chief Financial Officer
03/04/24 Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
02/07/24 Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
01/19/24 Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
APLM Chatroom

User Image sighed Posted - 3 hours ago

$CTNT $ZJK $PSQH $APLM free float under 600k, recent split reversing from lows.

User Image jkesh98 Posted - 19 hours ago

$APLM A watched pot doesn’t boil My alerts are set…🫡

User Image CocaKolla Posted - 19 hours ago

$APLM looks good

User Image fromtheothersid3 Posted - 21 hours ago

$APLM some volume coming in... Micro float Close above 11 today and See a nice Leg Up Chart is primed

User Image FLCaptain Posted - 23 hours ago

$APLM Out at 9.25. Bit early but not bad from 7.51. I’ll grab the next dip for round 3. This thing is a creeper.

User Image sighed Posted - 1 day ago

$APLM

User Image ShadowOfHELL Posted - 11/30/24

$APLM feeling weird. Ready to get in. Lets see some volume action next week. Maybe Huge leg up incoming?!

User Image fromtheothersid3 Posted - 11/29/24

$APLM 15++++ next week

User Image sighed Posted - 11/29/24

$APLM

User Image jkesh98 Posted - 11/29/24

$APLM HTB

User Image GJ_Rockabilt Posted - 11/29/24

$APLM I have a Sell Order up on some of APLMW Warrants, as a courtesy.

User Image stockWare Posted - 11/29/24

$SILO solid news, company has new partner to fund research and development. $DRUG $APLM $QSI

User Image FLCaptain Posted - 11/27/24

$APLM Holding nice from that 7.51 low yesterday. I’ll wait a bit more.

User Image smarterthanpaper Posted - 11/27/24

$APLM Non compliant Market cap going to sink like a stone, Even with a cash runway till 2025 they are going to have to dilute the hell outta shareholders. Aug 13th webcast they was asked when they could expect results on 3 different trials and gave we don't know answers

User Image FLCaptain Posted - 11/26/24

$APLM In at 7.51 for a swing.

User Image Botaeng Posted - 11/26/24

$APLM back to under a dollar with in a week... Possibly 2weeks?

User Image sighed Posted - 11/26/24

$APLM I’ve never seen a CTB this high. Over 1,000%

User Image P_etheris Posted - 11/26/24

$APLM Didn’t age well🤦‍♂️ Are you paid or just naturally 🧠 deficient ??? I am trying to save people here from fatal loses, constantly over different boards, but some of you are just unsavable…

User Image GJ_Rockabilt Posted - 11/25/24

$APLM Run Bears, run. Stampede!

User Image Gokuvegeta26 Posted - 11/25/24

$INUV $APLM This going to $1 bout to start Halting upwards fast😊

User Image fromtheothersid3 Posted - 11/25/24

$APLM nope

User Image sighed Posted - 11/25/24

$APLM

User Image SogCityRider Posted - 11/25/24

$APLM what price range do y’all see this closing

User Image sighed Posted - 11/25/24

$APLM zero shares to borrow.

User Image sighed Posted - 11/25/24

$APLM short sellers at it with this one, needs volume and eyes to move. these 1 share orders keep the price pinned.

User Image sighed Posted - 11/25/24

$APLM free float after split is under 600k. 👀

User Image Jrn2245 Posted - 11/25/24

$APLM Please check my post history. There was a user warning us about this. Leave at market open. It will be a slaughterhouse. Lick your wounds

User Image macec Posted - 11/25/24

$APLM I missed the memo and have been locked out of my account for days. What happened here?

User Image tradingcalendar Posted - 11/25/24

$GPUS 1-for-35 reverse stock split Share float reduced to 1.1M from 38.8M $APLM 1-for-100 reverse split Shares outstanding reduced to 1.1M from 109M $PBM 1-for-75 reverse stock split Shares outstanding reduced to 845K from 63.4M

User Image P_etheris Posted - 11/24/24

$APLM LOOK AT THE CHART!!! THIS WILL DROP ANOTHER 50%… I EXPECT DILUTION (offering) straight after R/S 🚨 🚨 🚨 🚨 🚨🚨 🚨 🚨 🚨 🚨 YOU BUY—-> YOU LOSE 🚨 🚨 🚨 🚨 🚨 🚨 🚨 🚨 🚨 🚨 YOU AVERAGE DOWN—-> YOU LOSE 🚨 🚨 🚨 🚨 🚨 🚨 🚨 🚨 🚨 🚨

Analyst Ratings
HC Wainwright & Co. Buy May 8, 24
EF Hutton Buy Apr 1, 24
HC Wainwright & Co. Buy Apr 1, 24
HC Wainwright & Co. Buy Nov 20, 23
HC Wainwright & Co. Buy Oct 3, 23
HC Wainwright & Co. Buy Jun 5, 23
HC Wainwright & Co. Buy Jun 1, 23
EF Hutton Buy Apr 25, 23